User profiles for "author:V Devauchelle-Pensec"

Valérie Devauchelle-Pensec

EA2216 INSERM ERI29
Verified email at chu-brest.fr
Cited by 10421

Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review

…, Z Alavi, SJ Bowman, V Devauchelle-Pensec… - …, 2016 - academic.oup.com
Objective. Ultrasonography (US) is a sensitive tool in the diagnosis of major salivary gland
abnormalities in primary Sjögren's syndrome (pSS). The aim of this systematic review was to …

Treatment of primary Sjögren syndrome

…, JO Pers, V Devauchelle-Pensec - Nature Reviews …, 2016 - nature.com
Primary Sjögren syndrome (pSS) is a progressive autoimmune disease characterized by
sicca and systemic manifestations. In this Review, we summarize the available data on …

B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment

D Cornec, V Devauchelle-Pensec, GJ Tobón… - Journal of …, 2012 - Elsevier
Primary Sjögren's syndrome (pSS) is a chronic autoimmune systemic disease, characterized
by a lymphoplasmocytic infiltration and a progressive destruction of salivary and lachrymal …

[HTML][HTML] COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

…, F Detree, V Devauchelle-Pensec… - The Lancet …, 2021 - thelancet.com
Background Various observations have suggested that the course of COVID-19 might be
less favourable in patients with inflammatory rheumatic and musculoskeletal diseases …

Treatment of primary Sjögren syndrome with rituximab: a randomized trial

V Devauchelle-Pensec, X Mariette… - Annals of internal …, 2014 - acpjournals.org
Background: Primary Sjögren syndrome (pSS) is an autoimmune disorder characterized by
ocular and oral dryness or systemic manifestations. Objective: To evaluate efficacy and …

Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial

…, JJ Dubost, S Rist, A Saraux, V Devauchelle-Pensec… - Jama, 2014 - jamanetwork.com
Importance Primary Sjögren syndrome is a systemic autoimmune disease characterized by
mouth and eye dryness, pain, and fatigue. Hydroxychloroquine is the most frequently …

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity …

…, V Le Guern, V Devauchelle-Pensec… - Annals of the …, 2016 - ard.bmj.com
Objectives To define disease activity levels, minimal clinically important improvement (MCII)
and patient-acceptable symptom state (PASS) with the primary Sjögren's syndrome (SS) …

Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper

…, F Buttgereit, V Devauchelle-Pensec… - … England Journal of …, 2023 - Mass Medical Soc
Background More than half of patients with polymyalgia rheumatica have a relapse during
tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 …

Improvement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20)

V DevauchellePensec, Y Pennec… - Arthritis care & …, 2007 - Wiley Online Library
Improvement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20) -
Devauchelle‐Pensec - 2007 - Arthritis Care & Research - Wiley Online Library Skip to Article …

[HTML][HTML] Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome …

…, J Benessiano, V Devauchelle-Pensec… - PloS one, 2013 - journals.plos.org
Objectives To analyze the clinical and immunological characteristics at enrollment in a large
prospective cohort of patients with primary Sjögren's syndrome (pSS) and to investigate the …